Cancer History Is Associated with Slower Speed of Cognitive Decline in Patients with Amnestic Cognitive Impairment
BACKGROUND: Several epidemiological studies report a negative association between Cancer and Alzheimer's disease (AD).
OBJECTIVE: To characterize the trajectories of memory loss in individuals with early amnestic cognitive impairment with and without history of previous cancer.
METHODS: Cognitive deterioration was assessed using the Montreal Cognitive Assessment (MoCA) or MoCA-Memory Index Score (MoCA-MIS) biannually in subjects with early amnestic cognitive impairment followed-up retrospectively from 2007 to 2021. History of Cancer was obtained from clinical records. Simple linear regressions of MoCA-MIS scores were calculated for each subject and analyzed with K-means cluster analysis to identify subgroups with different cognitive decline trajectories. χ2 and t tests were used for descriptive categorical and continuous variables and mixed multiple linear regressions to determine cognitive decline covariates.
RESULTS: Analysis of the trajectory of cognitive decline in 141 subjects with early amnestic cognitive impairment identified two subgroups: Fast (n = 60) and Slow (n = 81) progressors. At baseline Fast progressors had better MoCA-MIS (p < 0.001) and functionality (CDR p = 0.02, AD8 p = 0.05), took less anti-dementia medications (p = 0.005), and had higher depression rates (p = 0.02). Interestingly, Fast progressors slowed their speed of memory decline (from 1.6 to 1.1 MoCA-MIS points/year) and global cognitive decline (from 2.0 to 1.4 total MoCA points/year) when Cancer history was present.
CONCLUSION: Two trajectories of amnestic cognitive decline were identified, possibly derived from different neurophysiopathologies or clinical stages. This study suggests that a history of previous Cancer slows down amnestic cognitive decline, specifically in a subgroup of subjects with depression at baseline and accelerated deterioration at follow-up.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:87 |
|---|---|
| Enthalten in: |
Journal of Alzheimer's disease : JAD - 87(2022), 4 vom: 10., Seite 1695-1711 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Castillo-Passi, Rolando I [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alzheimer’s disease |
|---|
| Anmerkungen: |
Date Completed 21.06.2022 Date Revised 22.07.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3233/JAD-215660 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340205563 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340205563 | ||
| 003 | DE-627 | ||
| 005 | 20231226004622.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3233/JAD-215660 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1133.xml |
| 035 | |a (DE-627)NLM340205563 | ||
| 035 | |a (NLM)35491784 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Castillo-Passi, Rolando I |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cancer History Is Associated with Slower Speed of Cognitive Decline in Patients with Amnestic Cognitive Impairment |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.06.2022 | ||
| 500 | |a Date Revised 22.07.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Several epidemiological studies report a negative association between Cancer and Alzheimer's disease (AD) | ||
| 520 | |a OBJECTIVE: To characterize the trajectories of memory loss in individuals with early amnestic cognitive impairment with and without history of previous cancer | ||
| 520 | |a METHODS: Cognitive deterioration was assessed using the Montreal Cognitive Assessment (MoCA) or MoCA-Memory Index Score (MoCA-MIS) biannually in subjects with early amnestic cognitive impairment followed-up retrospectively from 2007 to 2021. History of Cancer was obtained from clinical records. Simple linear regressions of MoCA-MIS scores were calculated for each subject and analyzed with K-means cluster analysis to identify subgroups with different cognitive decline trajectories. χ2 and t tests were used for descriptive categorical and continuous variables and mixed multiple linear regressions to determine cognitive decline covariates | ||
| 520 | |a RESULTS: Analysis of the trajectory of cognitive decline in 141 subjects with early amnestic cognitive impairment identified two subgroups: Fast (n = 60) and Slow (n = 81) progressors. At baseline Fast progressors had better MoCA-MIS (p < 0.001) and functionality (CDR p = 0.02, AD8 p = 0.05), took less anti-dementia medications (p = 0.005), and had higher depression rates (p = 0.02). Interestingly, Fast progressors slowed their speed of memory decline (from 1.6 to 1.1 MoCA-MIS points/year) and global cognitive decline (from 2.0 to 1.4 total MoCA points/year) when Cancer history was present | ||
| 520 | |a CONCLUSION: Two trajectories of amnestic cognitive decline were identified, possibly derived from different neurophysiopathologies or clinical stages. This study suggests that a history of previous Cancer slows down amnestic cognitive decline, specifically in a subgroup of subjects with depression at baseline and accelerated deterioration at follow-up | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Alzheimer’s disease | |
| 650 | 4 | |a cancer history | |
| 650 | 4 | |a cognitive decline | |
| 650 | 4 | |a memory | |
| 650 | 4 | |a mild cognitive impairment | |
| 700 | 1 | |a Vergara, Rodrigo C |e verfasserin |4 aut | |
| 700 | 1 | |a Rogers, Nicole K |e verfasserin |4 aut | |
| 700 | 1 | |a Ponce, Daniela P |e verfasserin |4 aut | |
| 700 | 1 | |a Bennett, Magdalena |e verfasserin |4 aut | |
| 700 | 1 | |a Behrens, María Isabel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Alzheimer's disease : JAD |d 1998 |g 87(2022), 4 vom: 10., Seite 1695-1711 |w (DE-627)NLM097527327 |x 1875-8908 |7 nnns |
| 773 | 1 | 8 | |g volume:87 |g year:2022 |g number:4 |g day:10 |g pages:1695-1711 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3233/JAD-215660 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 87 |j 2022 |e 4 |b 10 |h 1695-1711 | ||